$LUCD News

Lucid Diagnostics: Positioned For A Medicare-Driven Inflection

Lucid Diagnostics Inc. (LUCD) Shareholder/Analyst Call Prepared Remarks Transcript

Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case

Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.25

Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results

Lucid Diagnostics Inc. 2026 Q1 - Results - Earnings Call Presentation

Maxim Group Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

Lucid Diagnostics Inc (LUCD) Q1 2026 Earnings Call Highlights: Exceeding Test Targets and ...

LUCD Q1 2026 Earnings Transcript

Lucid Diagnostics Q1 Earnings Call Highlights

Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript

Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Misses Revenue Estimates

Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results

Lucid Diagnostics Q1 Adj. EPS $(0.07) Beats $(0.08) Estimate

Lucid Diagnostics Q1 Sales $1.256M Miss $1.383M Estimate

Hyperfine, Inc. (HYPR) Reports Q1 Loss, Beats Revenue Estimates

Lucid Diagnostics Inc. (LUCD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

10x Genomics (TXG) Reports Q1 Loss, Beats Revenue Estimates